2017
Aspirin Use and Reduced Risk of Pancreatic Cancer
Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao YT. Aspirin Use and Reduced Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 68-74. PMID: 27999143, PMCID: PMC5225096, DOI: 10.1158/1055-9965.epi-16-0508.Peer-Reviewed Original ResearchConceptsPancreatic cancerAspirin useRegular useConfidence intervalsLong-term aspirin useControl subjects frequencyLow-dose aspirinAvoidance of smokingBody mass indexPopulation-based studyUnconditional logistic regressionABO blood groupRisk-benefit analysisAspirin typeCagA seropositivityDiabetes mellitusMass indexCigarette smokingCardiovascular diseaseAspirinCancerCertain cancersLogistic regressionBlood groupSubjects frequency
2015
Association between Helicobacter pylori and pancreatic cancer risk: a meta-analysis
Schulte A, Pandeya N, Fawcett J, Fritschi L, Risch HA, Webb PM, Whiteman DC, Neale RE. Association between Helicobacter pylori and pancreatic cancer risk: a meta-analysis. Cancer Causes & Control 2015, 26: 1027-1035. PMID: 25951801, DOI: 10.1007/s10552-015-0595-3.Peer-Reviewed Original ResearchConceptsH. pylori seropositivityPancreatic cancer riskPylori seropositivityPancreatic cancerOdds ratioCancer riskAustralian population-based case-control studyConfidence intervalsH. pyloriPopulation-based case-control studyHelicobacter pyloriOverall associationStrain-specific associationsLaird random-effects modelAdjusted odds ratioCase-control studyCytotoxin-associated geneSignificant overall associationRandom-effects modelEnzyme-linked immunosorbentPancreatic cancer studiesCagA seropositivityMethodsBlood samplesEpidemiological studiesSeropositivity
2014
Helicobacter pylori Seropositivities and Risk of Pancreatic Carcinoma
Risch HA, Lu L, Kidd MS, Wang J, Zhang W, Ni Q, Gao YT, Yu H. Helicobacter pylori Seropositivities and Risk of Pancreatic Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2014, 23: 172-178. PMID: 24234587, PMCID: PMC3947155, DOI: 10.1158/1055-9965.epi-13-0447.Peer-Reviewed Original ResearchConceptsCagA-positive strainsPancreatic cancerPancreatic carcinomaCagA seropositivityPylori seropositivityPylori colonizationGastric acidityH. pyloriLarge population-based case-control studyPopulation-based case-control studyPancreas cancer riskParticular cancer siteVirulence protein CagAHelicobacter pylori seropositivityH. pylori seropositivityBody mass indexH. pylori colonizationCase-control studyHelicobacter pylori colonizationH. pylori CagAStrain typesPathophysiologic actionsVenipuncture specimensAntibody seropositivityCase patients
2010
ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study
Risch HA, Yu H, Lu L, Kidd MS. ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study. Journal Of The National Cancer Institute 2010, 102: 502-505. PMID: 20181960, PMCID: PMC2902822, DOI: 10.1093/jnci/djq007.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialBacterial ProteinsCase-Control StudiesConfounding Factors, EpidemiologicConnecticutEnzyme-Linked Immunosorbent AssayFemaleHelicobacter InfectionsHelicobacter pyloriHumansIncidenceMaleMiddle AgedOdds RatioPancreatic NeoplasmsConceptsNon-O blood typeH pylori seropositivityCase-control studyPancreatic cancerPylori seropositivityABO blood groupEnzyme-linked immunosorbent assayBlood typeBlood groupPopulation-based case-control studyNon-O blood groupControl subjects frequencyH pylori colonizationVirulence protein CagAHelicobacter pylori seropositivityPancreatic cancer riskO blood typeRandom digit dialingCagA seropositivityCase patientsH pyloriControl subjectsRisk factorsPylori colonizationCancer risk